Currency In USD
| Previous Close | 11.36 |
| Open | 11.38 |
| Day High | 11.74 |
| Day Low | 11.08 |
| 52-Week High | 25.77 |
| 52-Week Low | 3.51 |
| Volume | 1.07M |
| Average Volume | 1.39M |
| Market Cap | 957.22M |
| PE | -6.41 |
| EPS | -1.75 |
| Moving Average 50 Days | 12.73 |
| Moving Average 200 Days | 17.81 |
| Change | -0.14 |
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses an
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
GlobeNewswire Inc.
Jan 09, 2026 3:49 AM GMT
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwri
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 07, 2026 9:01 PM GMT
BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an u